<DOC>
	<DOCNO>NCT03002025</DOCNO>
	<brief_summary>The primary purpose study assess safety , tolerability , pharmacokinetics ( PK ) follow single-dose subcutaneous ( SC ) injection JNJ-64304500 healthy Japanese male participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Following Subcutaneous Injection JNJ-64304500 Healthy Japanese Caucasian Male Participants</brief_title>
	<detailed_description />
	<criteria>Participant must sign informed consent document prior study related procedure indicate understand purpose study include procedure require willing participate study Participant must willing able adhere study visit schedule , prohibition restriction specify protocol , protocol requirement Participant must body weight range 60 90 kilogram ( kg ) , inclusive , body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen . This determination must record participant 's source document initial investigator Participant must nonsmoker least 3 month prior study enrollment Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Participant active acute chronic infection ( include chronic recurrent invasive candidiasis ) diagnose latent infection Participant serious infection ( example , sepsis , pneumonia pyelonephritis ) , hospitalize receive intravenous ( IV ) antibiotics serious infection 2 month prior screen Participant ever nontuberculous mycobacterial infection opportunistic infection ( eg , cytomegalovirus , pneumocystosis , aspergillosis ) prior screen Participant history active granulomatous infection , include histoplasmosis coccidioidomycosis prior screen If participant chest radiograph within 3 month study drug administration radiograph show abnormality suggestive malignancy current active infection , include tuberculosis ( TB )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>